Last reviewed · How we verify
NCT07326150
Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Cancer
trial testing Sample Collection in Pancreatic Cancer Resectable in 70 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2027
Quick facts
| Lead sponsor | Zhejiang Cancer Hospital |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 70 |
| Start date | 8 December 2025 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Sample Collection — full drug profile →
Conditions studied
- Pancreatic Cancer Resectable — all drugs for Pancreatic Cancer Resectable →
- Pancreatic Cancer Non-resectable — all drugs for Pancreatic Cancer Non-resectable →
Sponsor
Zhejiang Cancer Hospital
Who can join
18 and older, any sex, with Pancreatic Cancer Resectable or Pancreatic Cancer Non-resectable. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a single-center, observational clinical trial designed to enroll a total of 70 pancreatic cancer patients. Tumor tissue sections from 60 patients will be retrospectively collected to establish a treatment response prediction model using spatial transcriptomics and other analyses. Fresh tumor tissue and blood samples from 10 patients will be prospectively collected to establish pancreatic cancer organoids and humanized immunocompetent mouse models for functional validation and exploration of the underlying molecular mechanisms.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07326150
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sample Collection
Trials testing the same drug.
- NCT07296965 — Oral Microbiome in Carotid Atherosclerosis · recruiting
- NCT06601803 — Surgiphor Us in TSA · Phase 4 · enrolling by invitation
- NCT06641856 — Respiratory Virome Diversity and Baseline Immunity in Healthy Individuals in Shanghai · recruiting
- NCT07271823 — Establishment of a Predictive Model for Immunotherapy Response in Pancreatic Cancer · active not recruiting
- NCT05725174 — Volatile Non-Invasive Biomarkers of Epileptic Seizures · recruiting
Other recruiting trials for Pancreatic Cancer Resectable
Currently open trials in the same condition.
- NCT07081360 — Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer · Phase 3 · recruiting
- NCT06914349 — Antecolic Versus Retrocolic Gastrojejunostomy During Whipple's Procedure · NA · recruiting
- NCT07157605 — Oncological Safety of Spleen Preservation in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID) · recruiting
- NCT06722911 — Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer · Phase 2 · recruiting
- NCT06496373 — Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer · EARLY_PHASE1 · recruiting
Other Zhejiang Cancer Hospital trials
Trials by the same sponsor.
- NCT07343479 — Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases · Phase 2 · not yet recruiting
- NCT07441720 — Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT) · Phase 2 · recruiting
- NCT07416890 — Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Ref · Phase 2 · recruiting
- NCT07330544 — A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Rec · Phase 2 · recruiting
- NCT07235930 — Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced P · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07326150 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhejiang Cancer Hospital
- Last refreshed: 8 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07326150.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing